C. Lin

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

G. Sonpavde, M. Ernstoff, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Advances in Non-Surgical Treatment of Peyronie's Disease

J. Ma, W. Wang, C. Lin, 2018 .

Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial.

C. Hsu, C. Yang, A. Cheng, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results

M. Beeram, A. Patnaik, A. Gianella-Borradori, 2007 .

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

E. Rock, E. Van Cutsem, B. Melichar, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer.

K. Yeh, Y. Chao, Y. Shen, 2016, Journal of Clinical Oncology.

A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies.

T. Taube, W. Su, H. Fritsch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.